Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.
Brief Summary: The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.


Options:
A: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care
B: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alkylating Agents | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Disulfiram, Dietary Supplement: Copper, Drug: Alkylating Agents | Intervention Type: DRUG; Name: Disulfiram; Assigned to Arm(s): Experimental | Intervention Type: DIETARY_SUPPLEMENT; Name: Copper; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Alkylating Agents; Assigned to Arm(s): Control, Experimental
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: cognitive assessment; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm 1, Arm 2

Answer: A